BioSpace News Archive

Locanabio, Inc. today announced that Jim Burns, Ph.D., Locanabio’s chief executive officer, will provide a corporate overview at 5:30 pm. ET on Monday, October 2nd at Chardan’s 7th Annual Genetic Medicines Conference which is being held in New York City.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation.

Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes with chimeric antigen receptor technology developed by the Max Delbrück Center.

The Japanese Ministry of Health, Labor, and Welfare has granted marketing authorization for ALTUVIIIO®, a first-in-class, high-sustained factor VIII replacement therapy.

BioArctic AB’s partner Eisai announced that “LEQEMBI® Intravenous Infusion” has been approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease.

Pierre Fabre Laboratories and Vernalis Ltd, a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets.

On September 15, “Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery” successfully kicked off.

Alvotech announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd., has received marketing approval for AVT04, a biosimilar to Stelara®, from the Japanese Ministry of Health, Labor and Welfare.

Reviva Pharmaceuticals Holdings, Inc. announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study.

Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application on August 17, 2023, and was accepted for review by the US Food and Drug Administration on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics.